Showing 5 posts of 5 posts found.


Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial

July 11, 2019
Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma

Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …


Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine

May 8, 2019
Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …


Teva terminates Ajovy at Phase 3 in episodic cluster headache

April 24, 2019
Research and Development Teva, ajovy, headache, pharma

Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy …


Teva axes Phase 3 trial into chronic cluster headache

June 18, 2018
Research and Development, Sales and Marketing Teva, fremanezumab, headache, pharma

With the advent of another week, there’s another trial discontinuation in the industry as Teva announces its decision to terminate …


Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form

May 16, 2018
Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma

Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …

Latest content